Damoctocog alfa pegol in patients aged 7 to<12; an interim analysis of the Alfa-PROTECT extension

Hämostaseologie 2026

View at publisher
Authors: Anthony K. C. Chan, Margareth C Ozelo, Matteo Luciani, Heidi Glosli, Kaan Kavaklı, Nasrin Samji, Monika Maas Enriquez, Gregory C. Makris, P Kaur, L C Oliveira, S Gupta, Guillermo Arbesú
+3 more Mauro R. Davoli, Maria Elisa Mancuso, S El Hadouchi
DOI: 10.1055/s-0045-1814554
Cited by: 0

Abstract

Introduction The safety and efficacy of damoctocog alfa pegol for the prevention and treatment of bleeding in previously treated children with severe hemophilia A has been re-examined in the Alfa-PROTECT trial (NCT05147662) and its 18-month extension. Here, we aim to evaluate the safety and efficacy of damoctocog alfa pegol in children aged 7 to

Fields of Study & Subjects

Hemophilia Treatment and Research Platelet Disorders and Treatments Blood transfusion and management

Publication details

Journal / source
Hämostaseologie
Volume
46
Issue
S 01
Pages
S38–S39
Publication date
1 February 2026
Language
DE